Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.
Publication/Presentation Date
3-1-2021
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.
Volume
17
Issue
3
First Page
1009383
Last Page
1009383
ISSN
1553-7374
Published In/Presented At
Kurup, D., Malherbe, D. C., Wirblich, C., Lambert, R., Ronk, A. J., Zabihi Diba, L., Bukreyev, A., & Schnell, M. J. (2021). Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. PLoS pathogens, 17(3), e1009383. https://doi.org/10.1371/journal.ppat.1009383
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
33765062
Department(s)
Administration and Leadership
Document Type
Article